Page 2 - Sanket Koul

CDSCO asks states, UTs to mandate raw material tests for drugmakers

The drug regulator has asked states and UTs to enforce raw material testing and vendor qualification by manufacturers, following concerns over contaminated cough syrups and drug safety.

Indian MBBS aspirants seek a cheaper cure for seat crunch in Central Asia

Central Asia gains appeal on fees as junior doctor status in Georgia faces scrutiny over eligibility

Cipla Q2 net profit falls 35% to ₹878 cr as US business weighs on sales

Cipla's consolidated revenue declined 2.4% to Rs 7,404 crore in Q2 FY27 as its North America and API businesses weakened, while India revenue grew 12% to Rs 3,516 crore

Cap on cancer drug margins may not lower patients' medical bills: Experts

Experts warn that the 30% trade-margin cap on 137 anti-cancer drugs may offer limited relief to patients as assistance programmes remain excluded from price calculations.

Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business

The drugmaker's revenue rose 17.3 per cent to ₹4,338 crore in Q2 FY27, supported by strong demand for chronic therapies and growth in Bharat Serums and Vaccines' speciality portfolio.

Centre forms 3-member panel to review pharma marketing code, enforcement

The three-member committee will assess the effectiveness of the UCPMP, examine enforcement mechanisms and recommend measures to curb unethical pharmaceutical marketing practices

Domestic medtech industry backs DGHS ban on reuse of single-use devices

AIMED calls for stricter inspections, traceable disposal records and clear liability rules to protect patient safety

Torrent Pharma Q2 profit falls 9.6% to ₹534 crore, revenue rises 51%

Torrent Pharma's Q2FY27 net profit declined 9.6 per cent to ₹534 crore despite a 50.8 per cent rise in revenue, as higher finance costs and depreciation weighed on earnings

Bharat Biotech to cut malaria vaccine price by 40% under Gavi deal

The vaccine will be priced at €5.50 per dose from early 2027 under a Gavi-UNICEF agreement, with expected savings of $50 million through 2029

Signature Global enters senior living with Manasum, eyes ₹575 cr sales

The companies will develop 164 senior living units at Sarvam DXP in Gurugram, with prices starting at around Rs 3.7 crore per unit and handover expected in 48 months

Centre's cancer drug margin cap draws mixed response from industry, groups

The NPPA's 30% trade margin cap on 137 oncology drugs, effective November 9, has drawn support from the pharma industry, while patient groups question its impact on affordability.

Centre finalises 30% trade margin cap for 137 non-scheduled cancer drugs

New prices set to come into effect from November 9, 2026; state drug controllers to monitor implementation

Paras Health to use ₹375 cr from IPO to pare debt, plans 800-bed expansion

The ₹1,450-crore IPO comprises a ₹500-crore fresh issue and a ₹950-crore offer for sale, while the hospital chain plans to add 800 beds through projects in Gurugram and Ludhiana

CDSCO waives export NOC for approved r-DNA drugs sold under new brand names

The move is expected to reduce export approval timelines for biologics manufacturers using different brand names in overseas markets, provided the products are already approved in India

Centre directs states, UTs to display health service charges at all clinics

Union Health Ministry seeks prominent display of healthcare service charges and package rates for foreign patients travelling to India on medical or Ayush visas to improve transparency.

SC asks why drug price caps cannot extend beyond cancer medicines

Bench questions steep mark-ups on medicines and medical devices; Centre says price regulation must balance affordability with availability

After cancer drugs, medtech firms seek uniform trade margin cap for devices

Domestic manufacturers want importers' margins included in a uniform trade margin framework for medical devices, with a pilot covering high-volume consumables such as IV sets

Centre to cap trade margins on non-scheduled cancer drugs at 30%

Move could cut MRPs by up to 70%, save patients ₹2,500 crore annually; comes amid SC scrutiny of high mark-ups

IPM volume growth at 3.4% marks 2-yr high on steady demand across therapies

Volume growth reached 3.5 per cent, the highest in two years, while pricing rose about 6.2 per cent as most therapy segments recorded stronger demand

State scrutiny of pharma price mark-ups may lead to review of TMR policy

Drug regulators in Maharashtra, Karnataka and Uttar Pradesh are gathering data on price mark-ups, potentially strengthening the case for a review of trade margin rationalisation